Results: Of 157 screened patients, 86 were eligible for study enrollment. The patients' age ranged from 65 to 98 years (mean, 78 6 8.2 years). The cohort of patients consisted of 61 men and 25 women. Of the 86 patients, 48% (n ¼ 41) of patients were discharged with an opioid prescription, and 11.4% (n ¼ 10) of patients continued to receive opioids for 1 year (271-365 days). Patients with opioid use for 1 year were found to have a significantly higher incidence of diabetes, three or more different opioid prescribers, and three or more opioid-dispensing pharmacies. In addition, patients with 1-year opioid use had a significantly higher mean rank for duration of use of nonopioid pain medications (neuroleptics and benzodiazepines) compared with patients with opioid use up to 270 days after discharge (c 2 ¼ 31.8; P < .0005, KruskalWallis test).
POSTER SESSION

Arteriovenous Fistula Remains the Best Hemodialysis Access Choice for Some Elderly Patients
Objective: The optimal choice of hemodialysis access in elderly patients remains controversial. This study was undertaken to determine hemodialysis-dependent life expectancy by age of the patient at dialysis initiation and to compare this with the durability of the various hemodialysis access options.
Methods: We abstracted data from our center's hemodialysis electronic database during a 10-year period to determine survival of patients on hemodialysis, stratified by decade of life at dialysis initiation. We also collected data on each dialysis access to determine primary and secondary patency of access types in the various age subgroups. Kaplan-Meier survival functions were generated to represent patients' survival and hemodialysis access patency.
Results: There were 794 patients who started hemodialysis for chronic renal replacement therapy at our center during the study period. Patients in the ninth decade of life (80-89 years) had a median survival of 1.5 6 0.5 years on dialysis, but this represented two divergent groups of patients. Patients aged 80 to 89 years who were selected for arteriovenous fistula (AVF) creation and used this access survived a median of 3.0 6 0.9 years, whereas those patients who had an AVF but did not use it had a median life expectancy of 1.5 years. Patients who dialyzed only through a central venous catheter (CVC) had a median life expectancy of 0.8 6 0.2 years (Table) . There were no age-related differences in AVF patency (median secondary patency, 5.3 6 0.4 years; Fig) . The secondary patency of AVFs was superior to that of both arteriovenous grafts (1.9 6 0.8 years) and CVCs (1.5 6 0.4 years).
Conclusions: Patients who use an AVF have an increased median life expectancy. These patients have a life expectancy that exceeds the secondary patency of arteriovenous grafts and CVCs. In this subset of patients, AVF remains the best hemodialysis option. Objective: Bioresorbable cardiovascular stents are currently developed to reduce the risk of long-term thrombosis and restenosis in diseased vessels. However, absorbable polymers remain mechanically weaker and Table. Median dialysis-dependent life expectancy for patients who used an alternative access vs arteriovenous fistula (AVF) for dialysis vs patients who had an AVF created but that was never used because of failure of maturation or the patient's preference for dialysis through a central venous catheter (CVC) The P value for alternative access compared with AVF is < .001 for all age groups combined. have a relatively higher degree of stent recoil than metal does. Hence, we hereby intended to develop novel composite bioresorbable stents (cBRSs) made of poly(p-dioxanone) (PPDO) and polycaprolactone with mechanically reinforced compression performance for pediatric patients.
Methods: The cBRSs with PPDO monofilaments and PPDO-polycaprolactone composite braiding yarns were fabricated on a 32-bobbin braiding machine using different ratios (7:1 for cBRS type A and 3:1 for cBRS type B) and thermally treated in air thereafter. The properties of different prototypes compressed were evaluated by a parallel compression tester. Stent stress distribution and deformation mechanisms were also analyzed by the finite element method.
Results: Partial interlacing yarns were bonded, and the peeling force was as high as 2126.67 6 133.14 mN to restrict their movement greatly compared with the friction resistance (<100 mN) in the control group. The compression force was promoted dramatically in the novel composite prototype stents by 124.06% in cBRS type A and 169.58% in cBRS type B. Besides, the recovery abilities were also improved significantly. Moreover, deformation mechanisms revealed by computational simulations showed that bonded interlacing points among yarn played an important role.
Conclusions: This study demonstrated a novel technique for designing bioresorbable polymeric prototype stents with reinforced compression performance using a braiding and annealing procedure. The advantage of this design lies in the bonded strand interlacing points that restricted stent elongation and yarn gliding, which was revealed by computational simulations. In addition, the degradation behavior of novel composite braided stents will be evaluated in the future.
Author Disclosures: F. Zhao: Nothing to disclose; F. Wang: Nothing to disclose; L. Liu: Nothing to disclose; J. Wang: Nothing to disclose; M. King: Nothing to disclose; L. Wang: Nothing to disclose. Objective: Rates of cardiovascular and diabetes-related complications are generally decreasing. Whether a similar decline has occurred with lower extremity amputations remains poorly characterized. The aim of this study was to examine secular trends in the rate of lower extremity amputations among patients with diabetes and peripheral artery disease (PAD) within a single-payer regional health care system.
Lower Limb Amputations in Patients With
Methods: The study cohort included all individuals $40 years old who underwent diabetes or PAD-related lower limb amputation in Ontario, Canada (population, 13.6 million) between April 2005 and March 2016. Patients and amputations were identified through deterministic linkage of administrative health databases including inpatient and outpatient records. Quarterly rates (per 100,000 individuals $40 years old) of minor or major amputation as well as of major amputation alone were established. Time-series analyses were conducted using exponential smoothing models to characterize secular trends.
Results: A total of 19,961 patients underwent minor or major lower extremity amputations, of whom 12,755 (64%) underwent a major amputation. A total of 18,745 (94%) patients had PAD; 16,366 (82%) had diabetes; and 15,150 (76%) had both PAD and diabetes. The rate of any amputation initially declined between 2005 Q2 and 2010 Q4 but increased again by 2016 Q1 (Fig 1) , with PAD-related minor or major amputations following a similar trend (Fig 1) . A significant increase was observed in the rate of any amputation among patients with diabetes and those with diabetes and PAD (Fig 1) . Whereas the rates of major amputations decreased, albeit not significantly, among PAD patients, diabetes-related major amputations did not decrease (Fig 2) .
Conclusions: Diabetes-related lower extremity amputations have increased during the last decade. These data support renewed efforts to prevent and to decrease the burden of limb loss among patients with diabetes. 
